Reported record total revenue of $19.2 million in the fourth quarter of 2025 Scaling U.S. commercial launch of AYON Body Contouring System ™ (AYON) to meet strong market demand Expect FY2026...
CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion...
CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion...
CLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion...
CLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion...
CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion...
CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion®...
CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion®...